Carl has advised private equity firms on FCA investigations including s166 intervention and a pharma company on breach of HSE containment levels for pathogens which involved a counter-terrorism unit
Carl lead an internal investigation for a multinational alternative energy company who suspect fraudulent behaviour in this and other jurisdictions;
Carl has represented a director facing fraud charges connected to business dealings in the U.K, U.S and China (Hong Kong);
Carl was involved in advising an individual contacted by the SFO in respect of the ENRC investigation, advising a company contacted by the SFO with regard to the GSK investigation.
Carl represented a QC who is being privately prosecuted for fraud within a planning case;
He also advised a group CEO on a HMRC investigation into multi-million-pound tax evasion via the enterprise investment scheme (EIS).